Ergun Erdem, Heinzl Harald, Stur Michael
Department of Ophthalmology, University of Vienna Medical School, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Am J Ophthalmol. 2004 Sep;138(3):434-8. doi: 10.1016/j.ajo.2004.04.055.
To examine the influence of age, lesion size, degree of myopia, and baseline visual acuity on the visual outcome of patients with pathologic myopia and choroidal neovascularization (CNV) who received photodynamic therapy (PDT) with verteporfin.
Retrospective, noncomparative consecutive case series.
Forty-three eyes of 41 patients were treated in a two-year time span; 36 eyes of 36 patients who had received PDT for CNV due to pathologic myopia were examined for the above-mentioned factors 24 months after first treatment. All patients had been treated according to the Verteporfin in Photodynamic Therapy (VIP) study criteria. Patients were examined in two- to three-month intervals with Snellen visual acuity, biomicroscopy, and fluorescein angiography.
Baseline visual acuity and age were both prognostic factors for visual outcome (P =.0097, P =.0055). Lesion size (greatest linear dimension) at baseline, refractive error, or the number of treatments had no influence on the outcome.
Age and baseline visual acuity have an effect on visual outcome in patients receiving PDT due to CNV secondary to pathologic myopia. Younger patients and patients with higher baseline visual acuity had a better treatment outcome.
探讨年龄、病变大小、近视程度及基线视力对接受维替泊芬光动力疗法(PDT)的病理性近视合并脉络膜新生血管(CNV)患者视觉预后的影响。
回顾性、非对照连续病例系列。
在两年时间内对41例患者的43只眼进行了治疗;对36例因病理性近视性CNV接受PDT治疗的患者的36只眼在首次治疗后24个月检查上述因素。所有患者均按照光动力疗法用维替泊芬(VIP)研究标准进行治疗。每隔两到三个月对患者进行Snellen视力、生物显微镜检查和荧光素血管造影检查。
基线视力和年龄均为视觉预后的预后因素(P = 0.0097,P = 0.0055)。基线时的病变大小(最大线性尺寸)、屈光不正或治疗次数对预后无影响。
年龄和基线视力对因病理性近视继发CNV而接受PDT治疗的患者的视觉预后有影响。年轻患者和基线视力较高的患者治疗效果较好。